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Background
Hsp90 is a chaperone protein that binds client proteins
involved in the regulation of cell survival and apoptosis
signal transduction, including Akt, IKK complex, Apaf-
1, survivin, CDKs, and KSHVv F L I P .T h i sb i n d i n gi s
necessary to maintain proper protein folding, assembly,
transport, and function. A lack of Hsp90 results in
protein misfolding, ubiquitination, and degradation.
KSHV vFLIP was identified as a viral gene that is
responsible for NF-B-dependent anti-apoptotic gene
expression in primary effusion lymphoma (PEL) cells
[1]. In particular, the IKK signaling complex consisting
of IKKa,I K K b,I K K g,v F L I P ,a n dH s p 9 0i nt h ec a s eo f
PEL cells was demonstrated as essential for survival in
these cells. As Hsp90 forms part of the IKK signalo-
some in PEL cells, the Hsp90 inhibitor geldanamycin
was previously tested in these cells and has been
shown to inhibit activity of this complex in vitro. How-
ever, geldanamycin is of limited therapeutic potential
due to its undesirable pharmacophysiology. We tested
a new purine-scaffold Hsp90 inhibitor with high selec-
tivity for tumor versus normal cell Hsp90, which is
water-soluble with high oral bioavailability and excel-
lent therapeutic window [2,3].
Materials and methods
We evaluated the sensitivity of several KSHV infected
and uninfected cell lines to treatment with this inhibi-
tor, called PU-H71. We performed viability and NF-B
reporter luciferase assays. Immunoblot analyses to cel-
l u l a ra n dv i r a lp r o t e i n sw e r ed o n et oa s s e s st h ee f f e c t
of PU-H71. Finally, we used a mouse PEL xenograft
model and in vivo imaging to assess tumor responses
to PU-H71.
Results
We found all KSHV-positive PEL cell lines to be exqui-
sitely sensitive when compared to uninfected lymphoma
cells, with growth inhibition at IC50s in the nanomolar
range. PU-H71 was shown to induce PEL cell death by
apoptosis and autophagy within 48 hours of treatment.
Western blot analysis indicated that the IKK signaling
complex components vFLIP and IKKg were degraded
upon PU-H71 treatment, leading to destabilization of
the complex, and inhibition of NF-B signaling, as con-
firmed by reporter luciferase assay. PU-H71 was further
tested in a mouse xenograft model of PEL and shown to
inhibit progression of tumor spread and confer a signifi-
cant survival advantage (p<0.02) in these mice.
Conclusions
Our findings suggest that Hsp90 inhibition with PU-H71
is a promising targeted approach for the treatment of
PEL and warrants further preclinical and clinical
investigation.
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